%0 Journal Article
%T Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis
%A Alyson K. Myers
%A Deborah R. Gustafson
%A Eric Kupferstein
%A Haroon Kamran
%A Irini Youssef
%A James R. Sowers
%A Jocelyne G. Karam
%A Moro O. Salifu
%A Navneet Sharma
%A Samy I. McFarlane
%J Archive of "Cardiorenal Medicine".
%D 2018
%R 10.1159/000485196
%X Statins have long been prescribed for the primary and secondary prevention of cardiovascular disease (CVD) and kidney disease. Their benefits and efficacy are widely accepted in current clinical practice, but like any other therapeutic agents, they have adverse effects. One of the emerging concerns with statin therapy is the development of new-onset diabetes mellitus (NODM), a dreaded risk factor for CVD and kidney disease and widely viewed as CVD equivalent. Accumulating evidence indicates that NODM is a consequence of statin use
%K Statins
%K New-onset diabetes
%K Cardiovascular disease
%K Kidney disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968284/